Compound · clinical trials

Trastuzumab clinical trials

Also listed in trial records as Qutuozhudankang, TQB211, Zercepac, ABP 980, ALT02, Biceltis, CT-P06, CT-P6, Herclon, Hertraz, Herwenda

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 148 trials in our China, USA, Spain, South Korea, France, Italy, Germany, Belgium, Canada, Japan, UK, Brazil, Taiwan, Mexico, Australia, Poland, Israel, Netherlands, Portugal, Austria, Turkey, Norway, India, Singapore, Denmark, Czechia, Switzerland, Sweden, Ireland and Egypt registers that name Trastuzumab as an intervention. Synced 9 Nov 2026

148Current trials

82Recruiting now

96Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Trastuzumab is named as an intervention in 148 current clinical trials in our China, USA, Spain, South Korea, France, Italy, Germany, Belgium, Canada, Japan, UK, Brazil, Taiwan, Mexico, Australia, Poland, Israel, Netherlands, Portugal, Austria, Turkey, Norway, India, Singapore, Denmark, Czechia, Switzerland, Sweden, Ireland and Egypt registers. 82 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (8). The most-studied condition is Breast Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.

Trastuzumab also has an approved-drug profile on this site (FDA label data): Herceptin (Trastuzumab) →

Where Trastuzumab is approved

All regulators →

Of the three regulators tracked here, the first to approve Trastuzumab was the US, on 25 Sep 1998. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

25 Sep 1998

Herceptin

BLA103792 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

28 Aug 2000

Herceptin

EMA product page

First centralised authorisation

CACanada (Health Canada)

13 Aug 1999

Herceptin

Notice of Compliance 2072

First new-drug NOC

6 FDA-approved biosimilars: Hercessi, Herzuma, Kanjinti, Ogivri and others
2 EU safety letters (DHPC), latest: quality defect for RoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq, 17 Aug 2023

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Trastuzumab

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$58.2m

28,678 prescriptions in 2025 · Ogivri, Herceptin, Kanjinti

-4% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Trastuzumab works

All drug targets →

Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor
Target: ERBB2 erb-b2 receptor tyrosine kinase 2
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on ERBB2

Pertuzumab Trastuzumab deruxtecan Disitamab Vedotin Pyrotinib Trastuzumab emtansine Tucatinib Afatinib Zanidatamab Neratinib Dacomitinib KN026 Lapatinib +3 more

Diseases it has been tested for in clinical trials, by furthest phase

Biliary tract cancerPhase 3
CholangiocarcinomaPhase 3
Colon carcinomaPhase 3
Colorectal cancerPhase 3
Ductal breast carcinoma in situPhase 3
Endometrial cancerPhase 3
Esophageal adenocarcinomaPhase 3
Esophageal cancerPhase 3
Gallbladder cancerPhase 3
Gastroesophageal junction adenocarcinomaPhase 3

83 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201585, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 5082, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Trastuzumab

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 4 technology appraisals of Trastuzumab. 4 are current, and 3 of these recommend it for at least some patients.

Appraisal	NICE recommendation	Published	Status
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 NICE TA257	Not recommended	27 Jun 2012	Current
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer NICE TA208	Optimised	24 Nov 2010	Current
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer NICE TA107	Recommended	23 Aug 2006	Current
Guidance on the use of trastuzumab for the treatment of advanced breast cancer NICE TA34	Recommended	15 Mar 2002	Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Trastuzumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 17 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Herceptin, Tuznue, Dazublys (biosimilar), Herwenda (biosimilar), Herzuma (biosimilar), Kanjinti (biosimilar), Ogivri (biosimilar), Ontruzant (biosimilar) and 2 more
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Trastuzumab

ATC code: L01XC03
ChEMBL: CHEMBL1201585
DrugBank: DB00072
CAS number: 180288-69-1
FDA UNII: P188ANX8CK
Wikidata: Q412616
Wikipedia: Trastuzumab

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting8255%
Not yet open139%
Active, closed5235%
By invitation11%

Trials by phase

Phase 27047%
Phase 34128%
Phase 1/2117%
Phase 1107%
Phase 2/375%
Phase 464%
Observational32%

Clinical trials of Trastuzumab

148 trials

Study	Phase	Status	Lead sponsor	Registers
A Study for the Neoadjuvant Treatment of Breast Cancer NCT05420454 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
A Study for the Adjuvant Treatment of Breast Cancer NCT05420467 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie NCT06031233 · ClinicalTrials.gov ↗ · Oncology, Infusion Reaction	Phase 4	Recruiting	Isala	Netherlands
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). NCT06217185 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Advanced Breast Cancer	Phase 4	Recruiting	Hebei Medical University Fourth Hospital	China
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer NCT05159193 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer NCT05188313 · ClinicalTrials.gov ↗ · Esophageal Cancer, Esophageal Adenocarcinoma	Phase 3	Recruiting	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer NCT05253651 · Colorectal Neoplasms	Phase 3	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Norway, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Personalized Medicine for Advanced Biliary Cancer Patients NCT05615818 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms	Phase 3	Recruiting	UNICANCER	France, Belgium
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. NCT05838066 · ClinicalTrials.gov ↗ · First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc	China
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer NCT05883852 · ClinicalTrials.gov ↗ · HER2 Positive Early Breast Cancer	Phase 3	Recruiting	Fudan University	China
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial NCT06278870 · ClinicalTrials.gov ↗ · HER2-positive Metastatic Breast Cancer, First-line Treatment	Phase 3	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer NCT06435429 · Metastatic HER2-positive Breast Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Canada, Brazil, Japan, South Korea, Australia
The Sagittarius Trial NCT06490536 · ClinicalTrials.gov ↗ · Colon Cancer Stage II, Colon Cancer Stage III	Phase 3	Recruiting	IFOM ETS - The AIRC Institute of Molecular Oncology	Germany, Spain, Italy
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer NCT06532006 · Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer	Phase 3	Recruiting	Shanghai Henlius Biotech	USA, China, Germany, Spain, Italy, Poland, Turkey, Brazil, Japan, South Korea, Australia
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT06731478 · Gastric Cancer, Gastroesophageal Junction Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab NCT06876714 · ClinicalTrials.gov ↗ · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS) NCT06992882 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Fudan University	China
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer NCT07003074 · Breast Cancer	Phase 3	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd	China
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer NCT07047365 · ClinicalTrials.gov ↗ · HER2-positive Advanced Breast Cancer	Phase 3	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd	China
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer NCT07057427 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Henan Cancer Hospital	China
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients NCT07062263 · Biliary Tract Cancer, HER2-positive Cancer, Advanced Cancer	Phase 3	Recruiting	Tata Memorial Centre	India
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT07118527 · ClinicalTrials.gov ↗ · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07315750 · ClinicalTrials.gov ↗ · Gastric Carcinoma	Phase 3	Recruiting	RemeGen Co., Ltd	China
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer NCT07377643 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD	China
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer NCT07441460 · ClinicalTrials.gov ↗ · Resectable HER2-positive Breast Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc	China
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer NCT07518173 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd NCT07683754 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive	Phase 3	Recruiting	Daiichi Sankyo	USA
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer NCT07779538 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3)	Phase 3	Recruiting	Shanghai Jiao Tong University School of Medicine	China
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer NCT06504732 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Solid Tumor	Phase 2/3	Recruiting	SUNHO（China）BioPharmaceutical CO., Ltd	China
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer NCT06891833 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939 · HER2-positive Breast Cancer	Phase 2/3	Recruiting	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer NCT02693535 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors	Phase 2	Recruiting	American Society of Clinical Oncology	Norway, Mexico
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) NCT03297606 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling NCT04341181 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasms	Phase 2	Recruiting	Ulrik Lassen	Denmark
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer NCT04481932 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Recruiting	Peking University	China
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction NCT04680442 · ClinicalTrials.gov ↗ · Breast Cancer, Heart Failure	Phase 2	Recruiting	Population Health Research Institute	Canada, Brazil
ATEMPT 2.0: Adjuvant T-DM1 vs TH NCT04893109 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-positive Breast Cancer	Phase 2	Recruiting	Dana-Farber Cancer Institute	Israel
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer NCT04993014 · ClinicalTrials.gov ↗ · Breast Neoplasms, HER2-positive Breast Cancer, Circulating Tumor Cell	Phase 2	Recruiting	AC Camargo Cancer Center	Brazil
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer NCT05292742 · ClinicalTrials.gov ↗ · Breast Cancer, Adjuvant Therapy	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers NCT05408845 · Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8	Phase 2	Recruiting	NRG Oncology	Mexico
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer NCT05638594 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer NCT05725200 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Oslo University Hospital	Norway
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease NCT05800275 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer	Phase 2	Recruiting	UNICANCER	France
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer NCT05900206 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Karolinska University Hospital	Sweden
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC NCT05918328 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-positive Breast Cancer	Phase 2	Recruiting	Henan Cancer Hospital	China
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy NCT05978648 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 2	Recruiting	wang shusen	China
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study NCT06016387 · HER2-positive Breast Cancer, LMD	Phase 2	Recruiting	Sunnybrook Health Sciences Centre	Canada
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer NCT06121700 · ClinicalTrials.gov ↗ · Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer	Phase 2	Recruiting	Fudan University	China
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer NCT06245356 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency	Phase 2	Recruiting	UNICANCER	France
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study NCT06254690 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer NCT06468280 · ClinicalTrials.gov ↗ · Gastric Cancer, GastroEsophageal Cancer	Phase 2	Recruiting	Shanghai Zhongshan Hospital	China
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer NCT06589830 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, Advanced Colorectal Cancer	Phase 2	Recruiting	Suzhou Teligene Ltd	China
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer NCT06649331 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)	Phase 2	Recruiting	Fudan University	China
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC NCT06927180 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3)	Phase 2	Recruiting	Henan Cancer Hospital	China
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer NCT07007559 · Breast Cancer, Metastatic	Phase 2	Recruiting	ALX Oncology Inc	UK, USA, France, Spain, Italy, Canada, South Korea, Singapore
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer NCT07102381 · HER2-positive Breast Cancer, Breast Cancer	Phase 2	Recruiting	Jazz Pharmaceuticals	USA, Germany, Spain, Italy, Mexico
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer NCT07193394 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer	Phase 2	Recruiting	Institut Curie	France
ctDNA in HER2+ EBC Neoadjuvant Treatment NCT07335081 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer NCT07340398 · ClinicalTrials.gov ↗ · HER2-positive Early Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer NCT07393425 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer NCT07402473 · HER2-positive Early-stage Breast Cancer	Phase 2	Recruiting	Rutgers, The State University of New Jersey	Israel
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy NCT07506057 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Biliary Tract Cancer, HER2	Phase 2	Recruiting	Xiujuan Qu	China
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer NCT07610720 · ClinicalTrials.gov ↗ · Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer NCT07616427 · ClinicalTrials.gov ↗ · HR+/HER2+ Early Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer NCT07647263 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression. NCT07788196 · ClinicalTrials.gov ↗ · IB-II Gastric Cancer	Phase 2	Recruiting	Xijing Hospital	China
A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy NCT07911280 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Samsung Medical Center	South Korea
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer NCT04802759 · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	USA, Spain, South Korea, Australia, Israel
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) NCT05749900 · ClinicalTrials.gov ↗ · HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer	Phase 1/2	Recruiting	Yonsei University	South Korea
A Study of DB-1310 in Advanced/Metastatic Solid Tumors NCT05785741 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	DualityBio Inc	USA, China
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread NCT06324357 · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 1/2	Recruiting	Boehringer Ingelheim	UK, USA, China, Germany, France, Spain, Italy, Belgium, Japan, South Korea
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients NCT06650332 · ClinicalTrials.gov ↗ · Metastatic HER2 Positive Gastroesophageal Junction Cancer	Phase 1/2	Recruiting	Zhejiang Cancer Hospital	China
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) NCT06686394 · Breast Neoplasms, Breast Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, Canada, Japan, South Korea, Israel
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor NCT07140393 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study NCT06162559 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Recruiting	The Netherlands Cancer Institute	Netherlands
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 · Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA, France, Spain, Brazil, South Korea, Australia
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors NCT07216105 · Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer	Phase 1	Recruiting	Fate Therapeutics	USA
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer NCT07093931 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Not yet open	Shandong Cancer Hospital and Institute	China
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy NCT04973319 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Not yet open	Shengjing Hospital	China
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer NCT05983094 · ClinicalTrials.gov ↗ · Breast Cancer, Neoadjuvant Therapy	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA) NCT06510465 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	RenJi Hospital	China
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer NCT07059338 · ClinicalTrials.gov ↗ · HER2 Positive, Colorectal Cancer (CRC)	Phase 2	Not yet open	Sun Yat-sen University	China
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. NCT07136974 · ClinicalTrials.gov ↗ · Breast Cancer, HER2 + Breast Cancer	Phase 2	Not yet open	Henan Cancer Hospital	China
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study NCT07179939 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Not yet open	Fudan University	China
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer NCT07246317 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. NCT07528898 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Hebei Medical University Fourth Hospital	China
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) NCT07565324 · ClinicalTrials.gov ↗ · HER-2 Positive Breast Cancer	Phase 2	Not yet open	National Taiwan University Hospital	Taiwan
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer NCT07766772 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer, Advanced Breast Cancer	Phase 2	Not yet open	Fujian Cancer Hospital	China
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer NCT07795424 · ClinicalTrials.gov ↗ · Breast Cancer, HR Positive, HER2 Positive Breast Cancer	Phase 2	Not yet open	Shengjing Hospital	China
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response NCT07856303 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Early Breast Cancer (EBC)	Phase 2	Not yet open	Fudan University	China
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study NCT06843681 · ClinicalTrials.gov ↗ · Breast Carcinoma in Situ	Phase 2	By invitation	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy NCT04928261 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Active, closed	Ottawa Hospital Research Institute	Canada
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial NCT02320435 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 3	Active, closed	Hoffmann-La Roche	China, Germany, France, Spain, Italy, Poland, Portugal, Brazil, Mexico, Japan, South Korea
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer NCT02947685 · ClinicalTrials.gov ↗ · HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer	Phase 3	Active, closed	Alliance Foundation Trials, LLC	Germany, France, Spain, Italy, Portugal, Mexico, Australia
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer NCT03595592 · ClinicalTrials.gov ↗ · Invasive Breast Cancer	Phase 3	Active, closed	Fondazione Michelangelo	Germany, Spain, Italy, Austria
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer NCT04193059 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Fudan University	China
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation NCT04208178 · Advanced HER2+Breast Cancer	Phase 3	Active, closed	Novartis Pharmaceuticals	USA, China, France, Spain, Italy, Belgium
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) NCT04784715 · Breast Cancer; HER2-positive; Metastatic	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy NCT04873362 · Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Portugal, Turkey, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer NCT05113251 · Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer NCT05132582 · HER2 Positive Breast Cancer	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers NCT05152147 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma	Phase 3	Active, closed	Jazz Pharmaceuticals	Ireland, UK, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma NCT05256225 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, South Korea
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) NCT05296798 · Locally Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Turkey, Brazil, Mexico, South Korea, Taiwan, Egypt
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer NCT06747338 · ClinicalTrials.gov ↗ · Early or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Shanghai JMT-Bio Inc	China
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer NCT07196774 · ClinicalTrials.gov ↗ · Early-stage or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer NCT02568839 · ClinicalTrials.gov ↗ · Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer	Phase 2/3	Active, closed	Thomas Hatschek	Sweden
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer NCT04290793 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2/3	Active, closed	Hebei Medical University Fourth Hospital	China
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients NCT05426486 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2/3	Active, closed	Caigang Liu	China
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer NCT05980481 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2/3	Active, closed	RemeGen Co., Ltd	China
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612 · Neoplasm Metastasis	Phase 2	Active, closed	Genentech, Inc	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Czechia, Norway, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) NCT02465060 · ClinicalTrials.gov ↗ · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel, Egypt
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial NCT02624973 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	Haukeland University Hospital	Norway
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. NCT03161353 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	MedSIR	Germany, France, Spain, Italy, Belgium, Portugal
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer NCT03414658 · Breast Cancer	Phase 2	Active, closed	Adrienne G. Waks	Israel
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer NCT03571633 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Operable Breast Cancer	Phase 2	Active, closed	Centre Leon Berard	France
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] NCT03747120 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Breast Cancer	Phase 2	Active, closed	University of Texas Southwestern Medical Center	Mexico
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy NCT04266249 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Germany, Spain, Italy, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer NCT04398914 · ClinicalTrials.gov ↗ · Breast Cancer Invasive	Phase 2	Active, closed	Shanghai Jiao Tong University School of Medicine	China
MARGetuximab Or Trastuzumab (MARGOT) NCT04425018 · ClinicalTrials.gov ↗ · Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers NCT04430738 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA, Mexico, Japan
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations NCT04579380 · Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, Germany, Spain, Italy, Belgium, Japan, South Korea
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) NCT04721977 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	Pfizer	Japan, South Korea, Taiwan
Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer NCT04759248 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	SOLTI Breast Cancer Research Group	Spain
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer NCT05041842 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer With a Isolated Brain Progression	Phase 2	Active, closed	UNICANCER	France
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC NCT05458674 · ClinicalTrials.gov ↗ · Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer	Phase 2	Active, closed	Criterium, Inc	USA, Mexico
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma NCT05715931 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer	Phase 2	Active, closed	Yu jiren	China
A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab NCT06681298 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Esophagogastric Junction, Perioperative Period	Phase 2	Active, closed	xiaohua li	China
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast NCT03304080 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Diseases	Phase 1/2	Active, closed	Icahn School of Medicine at Mount Sinai	Israel
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer NCT03379428 · Breast Neoplasms, Malignant Neoplasm of Breast	Phase 1/2	Active, closed	US Oncology Research	USA
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies NCT05081609 · Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1/2	Active, closed	Ascendis Pharma Oncology Division A/S	USA, Spain, Italy, Belgium, Poland, Canada, South Korea, Taiwan, Singapore, Australia
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread NCT02057133 · Breast Neoplasms	Phase 1	Active, closed	Eli Lilly and Company	USA
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer NCT03006172 · Breast Cancer, Solid Tumor	Phase 1	Active, closed	Genentech, Inc	UK, USA, France, Spain, Canada
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers NCT03448042 · Solid Tumors	Phase 1	Active, closed	Genentech, Inc	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Denmark, Canada, South Korea, Taiwan, Singapore, Australia
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC NCT03716180 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Active, closed	Dana-Farber Cancer Institute	Israel
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer NCT04188548 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA, China, France, Spain, Belgium, Japan, South Korea, Taiwan, Australia
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer NCT06239467 · Advanced Cancer, Breast Cancer, Advanced Solid Tumors	Phase 1	Active, closed	OnKure, Inc	USA, France, Spain, Italy, Belgium, South Korea
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors	Phase 1	Active, closed	Enliven Therapeutics	USA, France, Spain, Italy, Netherlands, Belgium, South Korea
Investigating Cardiovascular Adverse Events Related to Cancer Treatment NCT03199300 · ClinicalTrials.gov ↗ · Toxicity Due to Chemotherapy, Cardiovascular Morbidity, Cancer, Treatment-Related	Observational	Active, closed	University Medical Center Groningen	Netherlands
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II NCT05525858 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Solid Tumor, Metastatic Cancer	Observational	Active, closed	Seoul National University Bundang Hospital	South Korea
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment NCT06663787 · Breast Cancer, Metastatic, HER2 + Breast Cancer	Observational	Active, closed	Nagoya City University	Japan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Trastuzumab in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Trastuzumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
Optimization of De-EscalatiON strategies in early breast cancer 2026-527524-27-00 · Neoplasms	Phase 2	Authorised	Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS	Italy

Trastuzumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

17 single-substance products containing Trastuzumab on the HPRA medicines list.

Dazublys 150 mg powder for concentrate for solution for infusionCuraTeQ Biologics (Malta) Limited · EU/1/25/1949/001
Herceptin 150 mg powder for concentrate for solution for infusionRoche Registration GmbH · EU/1/00/145/001
Herceptin 600 mg solution for injection in vialRoche Registration GmbH · EU/1/00/145/002
Herwenda 150 mg powder for concentrate for solution for infusionSandoz GmbH · EU/1/23/1762/001
Herzuma 150 mg powder for concentrate for solution for infusionCelltrion Healthcare Hungary Kft. · EU/1/17/1257/001

All 17 Irish products →

Supply shortages

No entry for Trastuzumab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Trastuzumab

157 conditions

Breast Cancer43 HER2-positive Breast Cancer20 Breast Neoplasms7 Gastric Cancer6 Advanced Breast Cancer6 Metastatic Breast Cancer5 HER2-positive Gastric Cancer5 Esophageal Adenocarcinoma4 Solid Tumor4HER2 + Breast Cancer4Advanced Solid Tumor3 Advanced Solid Tumors3

All 157 conditions

Condition (as registered)	Trials
Breast Cancer	43
HER2-positive Breast Cancer	20
Breast Neoplasms	7
Gastric Cancer	6
Advanced Breast Cancer	6
Metastatic Breast Cancer	5
HER2-positive Gastric Cancer	5
Esophageal Adenocarcinoma	4
Solid Tumor	4
HER2 + Breast Cancer	4
Advanced Solid Tumor	3
Advanced Solid Tumors	3
HER-2 Positive Breast Cancer	3
Solid Tumors	2
Biliary Tract Neoplasms	2
Breast Cancer, Metastatic	2
Gastroesophageal Junction Adenocarcinoma	2
Advanced Cancer	2
HER2 Positive	2
HER2-positive Early Breast Cancer	2
Gastroesophageal-junction Cancer	2
Ovarian Cancer	2
Biliary Tract Cancer	2
Breast Cancer Early Stage Breast Cancer (Stage 1-3)	2
HER2-positive Metastatic Breast Cancer	2
Metastatic Colorectal Cancer	2
Lymphoma, Non-Hodgkin	2
Multiple Myeloma	2
Anatomic Stage II Breast Cancer AJCC v8	2
Colorectal Neoplasms	1
Gastric Neoplasms	1
Gastroesophageal Adenocarcinoma	1
Neoplasm Metastasis	1
Uterine Neoplasms	1
Uterine Cervical Neoplasms	1
Urologic Neoplasms	1
Breast Cancer; HER2-positive; Metastatic	1
Metastatic Gastric Adenocarcinoma	1
Gastroesophageal Junction Cancer	1
HER2 Positive Breast Cancer	1
Locally Advanced or Metastatic Breast Cancer	1
Metastatic HER2-positive Breast Cancer	1
PI3K Gene Mutation	1
HR Positive	1
Malignant Neoplasm of Breast	1
Advanced HER2+Breast Cancer	1
Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer	1
Endometrial Cancer	1
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	1
Colorectal Carcinoma	1
Gastric Adenocarcinoma	1
GEJ Adenocarcinoma	1
HER2 Positive Solid Tumors	1
HER2 Amplification	1
Locally Advanced Solid Tumor	1
Metastatic Solid Tumor	1
Platinum-resistant Ovarian Cancer	1
Monoclonal Antibody	1
Non-Small Cell Lung Cancer	1
Colorectal Cancer	1
Solid Tumor, Adult	1
HER2 Mutation-Related Tumors	1
HER2-positive Cancer	1
Unresectable Biliary Tract Carcinoma	1
HR+/HER2+ Early Breast Cancer	1
Urothelial Carcinoma	1
HER2	1
Adenocarcinoma of the Stomach	1
Adenocarcinoma of Esophagogastric Junction	1
Salivary Gland Carcinoma	1
Precision Therapy	1
Colorectal Cancer (CRC)	1
IB-II Gastric Cancer	1
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Gastric Carcinoma	1
Adenocarcinoma	1
Stomach Neoplasm	1
Oligometastatic Disease	1
Neoadjuvant Therapy	1
Breast Neoplasm	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Advanced/Metastatic Breast Cancer	1
HER2-Positive Metastatic Breast Cancer	1
Resectable HER2-positive Breast Cancer	1
HER2 Positive Early Breast Cancer	1
HER2-positive Advanced Breast Cancer	1
Early-stage or Locally Advanced HER2-positive Breast Cancer	1
Solid Cancer	1
GastroEsophageal Cancer	1
First-line Treatment	1
HR Positive, HER2 Positive Breast Cancer	1
Metastatic HER2 Positive Gastroesophageal Junction Cancer	1
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	1
Early Breast Cancer (EBC)	1
Adenocarcinoma of the Esophagogastric Junction	1
Perioperative Period	1
Triple Negative Breast Cancer (TNBC)	1
HER2-negative Breast Cancer	1
Breast Carcinoma in Situ	1
Stomach Neoplasms	1
Breast Cancer Invasive	1
Colorectal Cancer Metastatic	1
Advanced Colorectal Cancer	1
Adjuvant Therapy	1
Early or Locally Advanced HER2-positive Breast Cancer	1
Estrogen Receptor Positive Breast Cancer	1
Invasive Breast Cancer	1
Colon Cancer Stage II	1
Colon Cancer Stage III	1
Metastatic Gastroesophageal Adenocarcinoma	1
DPD Deficiency	1
Metastatic Breast Cancer ( HER2 Negative)	1
Unresectable Breast Cancer	1
Operable Breast Cancer	1
Metastatic Breast Cancer With a Isolated Brain Progression	1
Leptomeningeal Metastasis	1
Leptomeningeal Disease	1
Toxicity Due to Chemotherapy	1
Cardiovascular Morbidity	1
Cancer, Treatment-Related	1
Oncology	1
Infusion Reaction	1
Esophageal Cancer	1
Early-Stage Breast Carcinoma	1
Cancer	1
Tumors	1
Neoplasms	1
Neoplasia	1
Advanced Lymphoma	1
Advanced Malignant Solid Neoplasm	1
Bladder Carcinoma	1
Breast Carcinoma	1
LMD	1
Heart Failure	1
Circulating Tumor Cell	1
Endometrial Carcinoma	1
Endometrial Clear Cell Adenocarcinoma	1
Endometrial Dedifferentiated Carcinoma	1
Endometrial Endometrioid Adenocarcinoma	1
Anatomic Stage IIA Breast Cancer AJCC v8	1
Anatomic Stage IIB Breast Cancer AJCC v8	1
Anatomic Stage IIIA Breast Cancer AJCC v8	1
Metastatic Salivary Gland Carcinoma	1
Recurrent Salivary Gland Carcinoma	1
Stage III Major Salivary Gland Cancer AJCC v8	1
Stage IV Major Salivary Gland Cancer AJCC v8	1
Anatomic Stage I Breast Cancer AJCC v8	1
Early Stage HER2+ Breast Cancer	1
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer	1
Metastatic Cancer	1
HER2-positive Early-stage Breast Cancer	1
Breast Diseases	1
Stage II Breast Cancer	1
Stage III Breast Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in China	86	51
Clinical trials in USA	34	15
Clinical trials in Spain	33	12
Clinical trials in South Korea	31	13
Clinical trials in France	29	12
Clinical trials in Italy	28	10
Clinical trials in Germany	22	9
Clinical trials in Belgium	21	7
Clinical trials in Canada	20	10
Clinical trials in Japan	19	7
Clinical trials in UK	18	8
Clinical trials in Brazil	18	9
Clinical trials in Taiwan	17	4
Clinical trials in Mexico	17	4
Clinical trials in Australia	16	8
Clinical trials in Poland	15	6
Clinical trials in Israel	14	5
Clinical trials in Netherlands	12	6
Clinical trials in Portugal	11	3
Clinical trials in Austria	8	5
Clinical trials in Turkey	8	4
Clinical trials in Norway	7	4
Clinical trials in India	7	2
Clinical trials in Singapore	5	1
Clinical trials in Denmark	5	1
Clinical trials in Czechia	5	2
Clinical trials in Switzerland	3	1
Clinical trials in Sweden	3	1
Clinical trials in Ireland	2	1
Clinical trials in Egypt	2	0
EU register (CTIS)	1	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Trastuzumab trials

How many clinical trials are testing Trastuzumab?

148 current trials in our China, USA, Spain, South Korea, France, Italy, Germany, Belgium, Canada, Japan, UK, Brazil, Taiwan, Mexico, Australia, Poland, Israel, Netherlands, Portugal, Austria, Turkey, Norway, India, Singapore, Denmark, Czechia, Switzerland, Sweden, Ireland and Egypt registers name Trastuzumab (also registered as TQB211) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Trastuzumab trials recruiting patients?

Yes. 82 of the 148 trials are recruiting: 51 with sites in China, 15 with sites in USA, 12 with sites in Spain, 13 with sites in South Korea, 12 with sites in France, 10 with sites in Italy, 9 with sites in Germany, 7 with sites in Belgium, 10 with sites in Canada, 7 with sites in Japan, 8 with sites in UK, 9 with sites in Brazil, 4 with sites in Taiwan, 4 with sites in Mexico, 8 with sites in Australia, 6 with sites in Poland, 5 with sites in Israel, 6 with sites in Netherlands, 3 with sites in Portugal, 5 with sites in Austria, 4 with sites in Turkey, 4 with sites in Norway, 2 with sites in India, 1 with sites in Singapore, 1 with sites in Denmark, 2 with sites in Czechia, 1 with sites in Switzerland, 1 with sites in Sweden and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Trastuzumab clinical trials?

Fudan University (8), Hoffmann-La Roche (5), Seagen, a wholly owned subsidiary of Pfizer (4) and AstraZeneca (4), among 96 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Trastuzumab clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Trastuzumab licensed in Ireland?

Yes. The HPRA medicines list includes 17 single-substance products containing Trastuzumab, for example Dazublys 150 mg powder for concentrate for solution for infusion (CuraTeQ Biologics (Malta) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Trastuzumab shortage?

Not in the lists we track: Trastuzumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trastuzumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trastuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trastuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Trastuzumab clinical trials

Where Trastuzumab is approved

What health systems spend on Trastuzumab

How Trastuzumab works

NICE appraisals of Trastuzumab

Patient leaflets for Trastuzumab

Reference identifiers for Trastuzumab

Trials by status

Trials by phase

Clinical trials of Trastuzumab

Trastuzumab in the EU trials register (CTIS)

Trastuzumab across our data

Licensed in Ireland (HPRA)

Supply shortages

Conditions studied with Trastuzumab

Sponsors

By country register

Related compounds

In the same trials as Trastuzumab

Other compounds in Breast Cancer trials

Questions about Trastuzumab trials

How this page is built